Loading...
A recombinant chimeric protein specifically induces mutant KRAS degradation and potently inhibits pancreatic tumor growth
Pancreatic cancer is one of the most lethal human diseases, with an all-stage 5-year survival rate below 5%. To date, no effective and specific therapy is available for this disease. Mutations in KRAS are frequently reported in pancreatic and many other cancers; thus, KRAS is an attractive therapeut...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5190097/ https://ncbi.nlm.nih.gov/pubmed/27322423 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9996 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|